Page last updated: 2024-09-05

sorafenib and gsk2656157

sorafenib has been researched along with gsk2656157 in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(gsk2656157)
Trials
(gsk2656157)
Recent Studies (post-2010) (gsk2656157)
6,5207305,25129029

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)gsk2656157 (IC50)
Cytochrome P450 3A4Homo sapiens (human)0.245
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)0.905
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.0691
Eukaryotic translation initiation factor 2-alpha kinase 1Homo sapiens (human)0.46
Eukaryotic translation initiation factor 2-alpha kinase 3Homo sapiens (human)0.0154
eIF-2-alpha kinase GCN2Homo sapiens (human)3.388

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Shi, K; Wang, J; Wang, Y; Zhang, J; Zhou, E1

Reviews

1 review(s) available for sorafenib and gsk2656157

ArticleYear
Small-Molecule Receptor-Interacting Protein 1 (RIP1) Inhibitors as Therapeutic Agents for Multifaceted Diseases: Current Medicinal Chemistry Insights and Emerging Opportunities.
    Journal of medicinal chemistry, 2022, 11-24, Volume: 65, Issue:22

    Topics: Apoptosis; Chemistry, Pharmaceutical; Drug Discovery; Humans; Receptor-Interacting Protein Serine-Threonine Kinases

2022